All Stories

Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition.

Feb 14, 2025 - 16:57
 0
Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition.
Read More

Tags:

Previous Article

Happening Now: Delta Pays $1.4 Billion Profit Sharing, Topping All Other U.S. Ai...

Next Article

Human medicines European public assessment report (EPAR): Zinforo, ceftaroline f...

Related Posts

Kallyope links oral obesity combo to 3% weight loss, rejigs pipeline as migraine asset advances

Kallyope links oral obesity combo to 3% weight loss, re...

Feb 27, 2025  0

Viracta Therapeutics hits end of the line, laying off all workers and winding down

Viracta Therapeutics hits end of the line, laying off a...

Feb 9, 2025  0

Michigan CRO buys Exploristics for its cloud-based modeling platform

Michigan CRO buys Exploristics for its cloud-based mode...

Feb 12, 2025  0